The biopharmaceutical company's Q3 update was music to investors' ears.
/PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of TG Therapeutics, Inc. ("TG Therapeutics" or the "Company") (NASDAQ: TGTX). Such...
The drugmaker delivered a couple of surprises in Q2.
These three biotech stocks were on the volatile side today.
TG Therapeutics (TGTX) delivered earnings and revenue surprises of 22.22% and 105.94%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?
All three companies have therapies with strong sales potential.